EUCTR2007-006303-21-GB进行中（未招募）1 期
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Submental fat that is considered undesirable by the participant and graded by the Investigator as 2 or 3 using the SMF Rating Scale (Appendix C of the protocol).
- •2. Males or nonpregnant, nonlactating females who are aged 25 to 65 years, inclusive, on the date of randomization. Females of childbearing potential must have a negative human chorionic gonadotropin (HCG) test result within 28 days before randomization and must agree to practice adequate contraception, in the judgment of the investigator, during the course of the trial.
- •3. History of maintenance of a stable body weight, in the judgement of the Investigator, for at least 6 months before randomization.
- •4. The subject is expected to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
- •5. The subject is medically able to undergo the administration of study material as determined by clinical and laboratory evaluations (section 7 of the protocol) obtained within 28 days before randomization, for which the investigator identifies no clinically significant abnormality.
- •6. Signed informed consent obtained before any study specific procedure is conducted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of any intervention to treat submental fat (e.g. liposuction) or trauma associated with the chin or neck areas, which in the judgment of the investigator, may affect safety or efficacy evaluation of the treatment.
- •2. Loose skin in the neck or chin area for which reduction in submental fat may, in the judgement of the Investigator, result in a cosmetically unacceptable outcome.
- •3. Prominent platysmal bands at rest that interfere with the evaluation of submental fat.
- •4. Evidence of any cause of enlargement in the submental area (eg. thyroid enlargement, cervical adenopathy) other than localised submental fat.
- •5. Fitzpatrick Skin Type IV, V, or VI (Appendix B of the protocol).
- •6. Currently on, or considering starting, a weight reduction regimen.
- •7. Any medical condition (e.g. respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction), that would interefere with the assessment of safety or efficacy in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent.
- •8. Treatment with fish oil or nonsteroidal anti-inflammatory agents (NSAIDs) within seven days before randomisation, or any anticipated need for agents with anticoagulative effects (e.g. warfarin, heparin) during the course of the trial. Aspirin used for prophylaxis will be allowed.
- •9. Treatment with oral anticoagulants (e.g. warfarin) within 28 days before randomisation.
- •10. Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections within 6 months before randomization.
- •11. History of sensitivity to any components of the study material or to topical or local anaesthetics (e.g. lidocaine, benzocaine, novocaine).
- •12. Previous randomization into this trial.
- •13. Treatment with an investigational device or agent within 30 days before randomization.
研究者
相似试验
招募中
1 期
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Spontaneous Urticaria (CSU) to assess if it is effective and safe.Chronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code: 10072757Term: Chronic spontaneous urticaria Class: 100000004858CTIS2023-504799-94-00Escient Pharmaceuticals Inc.114
已完成
不适用
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to PneumoniaKCT0005344Enzychem Lifesciences Corporation60
进行中（未招募）
1 期
Clinical trial to compare the benefit and safety of a single infusion of VIS410, the study medicine added to standard Tamiflu® treatment to that of treatment with Tamiflu® alone in hospitalized adults with flu infection requiring oxygen supportInfluenza A infection in hospitalized patients who need supplemental oxygenMedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862EUCTR2016-004009-15-EEVisterra, Inc.120
进行中（未招募）
1 期
Clinical trial to compare the benefit and safety of a single infusion of VIS410, the study medicine added to standard Tamiflu® treatment to that of treatment with Tamiflu® alone in hospitalized adults with flu infection requiring oxygen supportInfluenza A infection in hospitalized patients who need supplemental oxygenMedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862EUCTR2016-004009-15-BEVisterra, Inc.120
进行中（未招募）
1 期
Clinical trial to compare the benefit and safety of a single infusion of VIS410, the study medicine added to standard Tamiflu® treatment to that of treatment with Tamiflu® alone in hospitalized adults with flu infection requiring oxygen supportEUCTR2016-004009-15-ESVisterra, Inc.390